Authors: Krista Spiller ZhengXiong Xi XiaoQing Peng Amy H Newman Charles R Ashby Christian Heidbreder József Gaál Eliot L Gardner
Publish Date: 2007/11/06
Volume: 196, Issue: 4, Pages: 533-542
Abstract
METH 01–065 mg/kg ip dosedependently lowered ∼10–50 BSR thresholds producing an enhancement of BSR Pretreatment with SB277011A 12 mg/kg but not 24 mg/kg ip significantly attenuated METHenhanced BSR NGB 2904 01–10 mg/kg but not 10 mg/kg also attenuated METHenhanced BSR SB277011A or NGB 2904 alone at the doses tested had no effect on BSR Pretreatment with BP897 01–5 mg/kg dosedependently attenuated METHenhanced BSR However when the dose was increased to 10 mg/kg BP897 shifted the stimulation–response curve to the right inhibited BSR itself in the presence or absence of METHSelective antagonism of D3 receptors by SB277011A or NGB 2904 attenuates METHenhanced BSR in rats while the METHenhanced BSR attenuation produced by BP897 may involve both D3 and nonD3 receptors These findings support a potential use of selective D3 receptor antagonists for the treatment of METH addictionAll authors hereby declare that except for income received from their respective primary employers no financial support or compensation has been received from any individual or corporate entity over the past 3 years for research or professional services There are no personal financial holdings that could be perceived as constituting a potential conflict of interest
Keywords: